Articles By Cyndi Root

  1. Teva, Active Biotech Expand Laquinimod Program In Neurodegenerative Diseases 11/7/2014

    Teva Pharmaceutical Industries and Active Biotech have expanded their partnership with new trials of laquinimod.

  2. Amgen's 1st Phase 3 Trial For Trebananib Reveals Disappointing Results 11/7/2014

    Amgen announced secondary endpoint results from the TRINOVA-1 trial of trebananib in women with recurrent ovarian cancer.

  3. Oncology Trials Facing Longer Cycle Times, Report Finds 11/6/2014

    According to a new KMR Group report, oncology trials are now taking longer to complete. KMR announced its findings in a press release, stating that late-stage oncology cycle times have increased in the last 10 years.

  4. ex scientia, Sunovion Partner On Treatments For Psychiatric Disorders 11/6/2014

    ex scientia has partnered with Sunovion Pharmaceuticals on treatments for psychiatric disorders.

  5. Kamada's Glassia Granted FDA Orphan Drug Status For Graft Versus Host Disease 10/31/2014

    Kamada announced in a press release that the Food and Drug Administration (FDA) has granted Glassia Orphan Drug status for the treatment of Graft-versus-host-disease (GVHD).

  6. FDA Delays Decision On NPS' Natpara BLA For Hypoparathyroidism 10/29/2014

    NPS Pharmaceuticals made a major amendment to its Biologics License Application (BLA) for Natpara, causing the Food and Drug Administration (FDA) to delay its decision for another three months.

  7. FDA Approves Arbor's Sotylize For Arrhythmias, Atrial Fibrillation 10/29/2014

    Arbor Pharmaceuticals has provided a new sotalol hydrochloride oral solution, Sotylize, for treatment of ventricular arrhythmias and maintenance of normal sinus rhythm in patients with atrial fibrillation/flutter

  8. FDA Allows Cytori To Resume ADRC Trial In Ischemic Heart Disease 10/29/2014

    Cytori Therapeutics has been allowed to resume its ATHENA trials for adipose-derived regenerative cells (ADRCs) in heart failure patients with ischemic heart disease.

  9. BCRP Blood Cancer Consortium Expands Clinical Trial Base 10/29/2014

    The Blood Cancer Research Partnership (BCRP) and the Dana-Farber Cancer Institute, the lead institute of the BCRP, have announced an expansion of the collaborative effort that includes Harvard University and members of industry.

  10. Relypsa Submits NDA For Patiromer In Hyperkalemia 10/28/2014

    Relypsa has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for patiromer in the treatment of hyperkalemia.